Table 1.
Clinical Trials Reporting Hyperglycemia/Diabetes with ICI use
| Reported cases(n) | Study (n) | Side effect (%) | Side effect | Drug | Cancer Type | Journal | Year | Reference |
|---|---|---|---|---|---|---|---|---|
| 4 | 135 | 2.96 | Hyperglycemia | Lambrolizumab | Melanoma | NEJM | 2013 | 10 |
| 13 | 287 | 4.52 | Hyperglycemia | Nivolumab | Lung | NEJM | 2015 | 11 |
| 9 | 406 | 2.21 | Hyperglycemia | Nivolumab | Renal cell | NEJM | 2015 | 12 |
| 1 | 206 | 0.48 | Diabetes | Nivolumab | Melanoma | NEJM | 2015 | 13 |
| 1 | 154 | 0.64 | Type 1 Diabetes | Pembrolizumab | Lung | NEJM | 2016 | 14 |
| 1 | 88 | 1.13 | Type 1 Diabetes | Avelumab | Merkel-cell | Lancet | 2016 | 15 |
| 1 | 26 | 3.84 | Hyperglycemia | Pembrolizumab | Merkel-cell | NEJM | 2016 | 16 |
| 2 | 452 | 0.44 | Diabetes | Nivolumab | Melanoma | NEJM | 2017 | 17 |
| 3 | 53 | 5.66 | Hyperglycemia | Avelumab | Solid tumors | Lancet | 2017 | 18 |
| 7 | 55 | 12.7 | Hyperglycemia | Avelumab | Renal cell | Lancet | 2018 | 19 |
| 4 | 300 | 1.33 | Hyperglycemia | Pembrolizumab | Squamous cell | Lancet | 2019 | 20 |
| 6 | 78 | 7.7 | Hyperglycemia | Cemiplimab | Cutaneous cell | Lancet | 2020 | 21 |
| 1 | 154 | 0.64 | Hyperglycemia | Pembrolizumab | Childhood tumors | Lancet | 2020 | 22 |